Review of diuretic resistance in cardiorenal syndrome covers natriuretic peptide biology, GLP-1 drug effects, and phenotype-guided management strategies.
Key findingReview of diuretic resistance in cardiorenal syndrome covers natriuretic peptide biology, GLP-1 drug
What the researchers found
Review of diuretic resistance in cardiorenal syndrome covers natriuretic peptide biology, GLP-1 drug effects, and phenotype-guided management strategies.
Why it matters
These findings are relevant to the growing population of patients using or considering peptide-based therapies.
The numbers in context
Up to one-third of heart failure patients develop diuretic resistance. Congestion drives most heart failure hospitalizations.
How the study worked
Study design and methodology detailed in the full publication.
Who was studied
Heart failure patients with diuretic resistance (cardiorenal syndrome)
What this study cannot tell us
Study limitations discussed in the full publication.
How to read the evidence
Evidence assessment based on study design in publication.
When this study was published
Published in 2025.
The bigger picture
This study contributes to the expanding evidence for peptide-based therapeutics in clinical medicine.
Questions still open
- What are the long-term implications?
- How do results compare to existing evidence?
- What further research is needed?
Common questions
What does this study mean for patients?
How reliable are these findings?
Read the original research
Diuretic resistance in cardiorenal syndrome: mechanisms, monitoring and phenotype-tailored management.
Frontiers in cardiovascular medicine, 12, 1731305
Citation
Aletras, Georgios; Bachlitzanaki, Maria; Stratinaki, Maria; Foukarakis, Emmanuel; Petrakis, Ioannis; Pantazis, Yannis; Hamilos, Michalis; Stylianou, Kostas. (2025). Diuretic resistance in cardiorenal syndrome: mechanisms, monitoring and phenotype-tailored management.. Frontiers in cardiovascular medicine, 12, 1731305. https://doi.org/10.3389/fcvm.2025.1731305